Copertina

A phase 1, multicenter, open‐label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Chay Ngee Lim, Gary Mo, Rajinder Bhardwaj, Craig M. Comisar, Beth L. Emerson, Kyle T. Matschke, Ogert Fisniku, Richard Bertz, Robert Croop, Jing Liu
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Headache: The Journal of Head and Face Pain
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of zavegepant nasal spray in healthy adults from two phase 1 randomized, placebo‐controlled trials
di: Richard Bertz, et al.
Pubblicazione: (2025)

Effects of multiple‐dose administration of zavegepant nasal spray on the single‐dose pharmacokinetics of ethinyl estradiol‐levonorgestrel
di: Rajinder Bhardwaj, et al.
Pubblicazione: (2024)

Assessment of pharmacokinetic and pharmacodynamic interactions between zavegepant and sumatriptan: A phase 1, randomized, placebo‐controlled study in healthy adults
di: Rajinder Bhardwaj, et al.
Pubblicazione: (2024)

Comparative bioavailability of single‐dose zavegepant during and between migraine attacks: A phase 1, randomized, open‐label, fixed‐sequence, two‐period study
di: Richard J. Bertz, et al.
Pubblicazione: (2024)

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine
di: David Kudrow, et al.
Pubblicazione: (2025)

Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial
di: Koichi Ikeda, et al.
Pubblicazione: (2025)

A phase 1 study of the breast milk and plasma pharmacokinetics of zavegepant 10 mg intranasal dose in healthy lactating women
di: Abhijeet Jakate, et al.
Pubblicazione: (2026)

Reduction of opioid and barbiturate use following initiation of rimegepant for migraine in the United States
di: Noah Rosen, et al.
Pubblicazione: (2025)

Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
di: Jessica Ailani, et al.
Pubblicazione: (2024)

Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo‐controlled clinical trials
di: Larry Charleston, et al.
Pubblicazione: (2026)

Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real‐life multicenter study
di: Julia Peris‐Subiza, et al.
Pubblicazione: (2025)

Sequential administration of peripheral nerve blocks and onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders—A retrospective tolerability and safety study
di: Christopher C. Anderson, et al.
Pubblicazione: (2024)

A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults
di: Richard B. Lipton, et al.
Pubblicazione: (2024)

Milk and plasma pharmacokinetics of single‐dose ubrogepant in healthy lactating women
di: Ramesh R. Boinpally, et al.
Pubblicazione: (2025)

Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study
di: Alba López‐Bravo, et al.
Pubblicazione: (2025)

Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial
di: Muneto Tatsumoto, et al.
Pubblicazione: (2024)

Cerebrovascular reactivity to hypercapnia in patients with migraine: A dual‐echo arterial spin labeling MRI study
di: E. S. Hoogeveen, et al.
Pubblicazione: (2024)

Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine
di: Anna de Dios, et al.
Pubblicazione: (2024)

Comparing single‐ and repeat‐dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial
di: Emmanuelle A. D. Schindler, et al.
Pubblicazione: (2025)

Evaluation of the effectiveness and safety of anti‐CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO ‐ CGRP study
di: María Clara García‐Castillo, et al.
Pubblicazione: (2026)

The safety and efficacy of onabotulinumtoxinA injections for children and adolescents with chronic migraine: A systematic review and meta‐analysis
di: Rebecca Lindsay, et al.
Pubblicazione: (2024)

Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura
di: Graham A. McLeod, et al.
Pubblicazione: (2025)

Letter to the Editor regarding “Persistence, effectiveness, and tolerability of anti‐calcitonin gene‐related peptide monoclonal antibodies in patients with chronic migraine”
di: Joaquín Borrás‐Blasco, et al.
Pubblicazione: (2025)

A critical appraisal of the International Classification of Headache Disorders migraine diagnostic criteria based on a retrospective multicenter cross‐sectional headache registry study in youth
di: Carlyn Patterson Gentile, et al.
Pubblicazione: (2024)

Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open‐label ASCEND acute migraine study
di: Jessica Ailani, et al.
Pubblicazione: (2025)

The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
di: Rikki Mangrum, et al.
Pubblicazione: (2024)

The effect of different exercise types on migraine frequency in individuals with migraine: A pilot study
di: Yunus Emre Meydanal, et al.
Pubblicazione: (2025)

A history of abuse is associated with more severe migraine‐ and pain‐related disability: Results from the American Registry for Migraine Research
di: Meesha Trivedi, et al.
Pubblicazione: (2024)

Low‐dose psilocybin in short‐lasting unilateral neuralgiform headache attacks: results from an open‐label phase Ib ascending dose study
di: James Rucker, et al.
Pubblicazione: (2024)

Evaluating associations of migraine‐related vertigo
di: Nazia Karsan, et al.
Pubblicazione: (2025)

Afterimage duration differs for migraine with or without aura
di: Florian Rimmele, et al.
Pubblicazione: (2025)

Mechanisms for mindfulness in migraine: Does catastrophizing matter?
di: Rebecca Erwin Wells, et al.
Pubblicazione: (2024)

Useful considerations for treating migraine in patients with autism
di: Sinifunanya E. Nwaobi
Pubblicazione: (2026)

Lifestyle triggers of migraine: Sleep restriction and caffeine lower the threshold for migraine‐like responses in rats in a sex‐specific manner
di: Gabriel Camargo de Oliveira, et al.
Pubblicazione: (2026)

Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study
di: Shuu‐Jiun Wang, et al.
Pubblicazione: (2024)

No association between migraine and HLA alleles in a cohort of 13,210 individuals with migraine from the Danish Blood Donor Study
di: Inga Zalia Tummoszeit, et al.
Pubblicazione: (2024)

Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features
di: Chia‐Chun Chiang, et al.
Pubblicazione: (2024)

Counting the cost: How migraine shapes lives and economies
di: Risako Shirane, et al.
Pubblicazione: (2025)

Cardiovascular risk and triptan usage among patients with migraine
di: Ido Peles, et al.
Pubblicazione: (2025)

Depression and anxiety are not associated with migraine outcomes in children and adolescents
di: Amy A. Gelfand
Pubblicazione: (2024)